Multiple Sclerosis
Ibogaine and MS (multiple sclerosis)
Two people with MS have been scanned before and after ibogaine and had the results published. One of them showed a 70% drop in lesion volume at three months. That is the entire record, and this page is short because the evidence is.
The first imaging of ibogaine in MS, and all of it
In 2025 a group published serial MRI scans from two people with MS who had been treated with ibogaine at a clinic in Tijuana, Mexico.⁵⁰ It is the first time anyone has looked at demyelinating disease this way, and it is worth understanding exactly what was and was not found.
2
people scanned
One man with relapsing-remitting MS, one woman with the secondary progressive form. Both treated at a single clinic in Mexico, both knew what they had taken.
70%
less lesion volume at three months
In the first of the two. Roughly 1,610 cubic millimetres of visible damage down to about 480.
Water moved differently
through the affected tissue
Diffusion tightened in a way that fits myelin being rebuilt and inflammation settling. It fits that reading. It does not prove it.
The second patient, a woman with the secondary progressive form of MS alongside long-standing trauma, showed changes in the cortex and in deeper structures, concentrated in the regions that handle pain and emotion. That is a different kind of finding from the first, and the authors report it as a description rather than an outcome.
MS is a myelin problem, and myelin is made by cells that can be pushed to grow
In MS the immune system strips the insulation off nerve fibres. That insulation is myelin, and it is laid down by cells called oligodendrocytes, which the adult brain still makes from a reserve of immature precursors. The precursors are usually there. What often fails is the step where they mature and wrap an axon.
The argument for looking at ibogaine is that its binding profile lines up unusually well with that step. Researchers ranking its receptor affinities against what white matter repair actually requires put it in a category of its own among psychedelic compounds: pushing myelin-making cells to mature, blunting the glutamate overload that damages nerve fibres, and supporting repair of the fibres themselves.⁵⁶ That is an argument built from binding data, not a demonstration that any of it happens in a person with MS.
The growth factor work points the same direction without being about MS at all. In animals a single dose raises GDNF and BDNF, the signals the brain uses to build and maintain connections.¹⁷ It is suggestive. It is also rodents.
For the underlying plasticity research in full, including what has and has not been measured in people, see what ibogaine does to the brain.
Two people is a reason to run a study, not a reason to believe one
There was no control group and no blinding. Everyone involved knew what had been taken and what they were hoping to see, and nobody has repeated it independently. Two scans at one clinic is the smallest unit of evidence that gets published at all.
MS also fluctuates on its own. In the relapsing-remitting form, lesions flare and fade with no help from anyone, which is the whole reason MS trials are built around control arms and long follow-up. A single person improving across three months cannot be told apart from the ordinary course of the disease.
And the wider picture has not changed. Every human efficacy finding for ibogaine, in any condition, still comes from open-label work, retrospective reviews and case reports, which is the weakest tier of evidence there is.⁵⁴ Ibogaine has never been shown to change how the immune system functions. It also carries a cardiac risk that has killed people who were not screened properly, which is why treatment belongs in hospital with monitoring and why some people are told no.
None of that makes the finding uninteresting. It makes it a starting point. If ibogaine turns out to do something for demyelinating disease, it will be a trial that shows it, and no such trial has begun.
Questions people actually ask
Citations (4)
[17] Marton S, González B, Rodríguez-Bottero S, et al. (2019). Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology, 10, 193. Read the source →
Rodent study showing that a single dose of ibogaine raises BDNF expression in the nucleus accumbens, substantia nigra, and prefrontal cortex, and selectively raises GDNF in the ventral tegmental area at the dose range effective in self-administration models.
[50] Chen DQ, et al. (2025). Neurorestorative effects of ibogaine in multiple sclerosis: serial MRI findings in two patients. Frontiers in Immunology. Read the source →
The first published neuroimaging data on ibogaine in multiple sclerosis. Two patients underwent serial MRI. One, a 41-year-old man with relapsing-remitting MS, showed a 70% reduction in lesion volume (1,609.8 to 480.5 mm3) at three months, with diffusion changes consistent with remyelination and reduced inflammation. The second, a 44-year-old woman with secondary progressive MS, showed cortical and subcortical changes. Two patients, one clinic, unblinded and uncontrolled: a first signal, not a result.
[54] Esperança MP, Gomes NG, Campos MG (2026). Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders. A Scoping Review. Molecules, 31(3), 545. Read the source →
Scoping review establishing the current tier of human evidence for ibogaine: no randomized, placebo-controlled trial has yet evaluated its efficacy in substance use disorders, and every human efficacy finding to date comes from open-label observational studies, retrospective analyses and case reports. Also covers the cardiac safety profile and the translational work now moving ibogaine into regulated clinical development.
[56] Calvey T, Govender D, Owen GR, Tumba N, Lang D, Lerer B, Stein DJ, Shoptaw S (2026). Neurorestorative properties of ibogaine: Linking multi-receptor affinities to remyelination and metabolic restoration. Acta Neuropsychiatrica, 38, e26. Read the source →
Argues from ibogaine's binding profile that it is unusually well placed among psychedelic compounds to support white matter repair, ranking its affinities at kappa-opioid, NMDA and sigma-2 receptors as the ones most relevant to oligodendrocyte maturation, protection against excitotoxic damage, and axonal repair. A mechanistic argument built on binding data, not a demonstration that any of it happens in a person with demyelinating disease.
Let’s connect.
No pressure. Tell us a little about what you’re going through.